SAM
LCTX icon

Smartleaf Asset Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Smartleaf Asset Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$239 Hold
177
– – ﹤0.01% 3286
2026
Q1 		$260 Buy
+177
New +$298 ﹤0.01% 3313

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Smartleaf Asset Management's LCTX Position: Q2 2026 in Review

Smartleaf Asset Management held its Lineage Cell Therapeutics (LCTX) position steady in Q2 2026 at 177 shares worth $239. The position accounts for ﹤0.01% of the portfolio, ranked #3286.

Smartleaf Asset Management first reported a position in LCTX in Q1 2026 and has held it in 2 quarters since. The position peaked at $260 in Q1 2026. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Smartleaf Asset Management held 177 shares of Lineage Cell Therapeutics worth $239 as of Q2 2026.
  • Smartleaf Asset Management left its Lineage Cell Therapeutics share count unchanged in Q2 2026.
  • Lineage Cell Therapeutics made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q2 2026, its #3286 holding.
  • Smartleaf Asset Management first reported a position in Lineage Cell Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Smartleaf Asset Management's Lineage Cell Therapeutics position peaked at $260 in Q1 2026.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Smartleaf Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.